Chang Liu, Yuan He, Xiaobing Xu, Lijun He, Baorong He* and Lingbo Kong* Pages 344 - 357 ( 14 )
Millions of people, especially for the aging people, are suffered by bone-loss diseases, such as rheumatoid arthritis (RA) and osteoporosis. Therefore, better understanding the involved mechanisms of bone metabolism is required for further treat on such diseases. Particularly, during the pathological process of bone losing, RANKL as a member of the tumor necrosis factor (TNF) superfamily, could induce osteoclast precursor cells differentiate into mature osteoclast, which grant its essential role in osteolysis. In recent years, with the increased attention paid to the natural compounds discovering studies, the therapeutic application of natural plant-derivatives have been widely recognized. Therefore, our present study aim to summarize the current novel research progressions on RANKL and its downstream signaling pathways in bone cellular differentiation, and provide a further insight for RANKL as the important drug targets in bone loss diseases. Besides that, in our current study, we also aim to briefly introduce the current application of several natural compounds for treating RANKL-mediated osteoclastic activation by modulating the RANKL signaling pathway and their therapeutic effects on the prevention of osteoporosis, osteoarthritis (OA) and RA.
RANKL, NF-κB, MAPKs, Akt, Ca2+, osteoporosis, osteoarthritis, rheumatoid arthritis, signaling pathways.
Department of Spine Surgery, Honghui Hospital Affiliated to Xi'an Jiaotong University, Xi'an, Department of orthopedics, Fifth Hospital of Xi'an, Xi'an, Department of neurosurgery, Shunde Hospital of Southern Medical University, Fo Shan, Department of Spine Surgery, Honghui Hospital Affiliated to Xi'an Jiaotong University, Xi'an, Department of Spine Surgery, Honghui Hospital Affiliated to Xi'an Jiaotong University, Xi'an, Department of Spine Surgery, Honghui Hospital Affiliated to Xi'an Jiaotong University, Xi'an